JP2002338494A - ムチン合成インヒビター - Google Patents

ムチン合成インヒビター

Info

Publication number
JP2002338494A
JP2002338494A JP2001316115A JP2001316115A JP2002338494A JP 2002338494 A JP2002338494 A JP 2002338494A JP 2001316115 A JP2001316115 A JP 2001316115A JP 2001316115 A JP2001316115 A JP 2001316115A JP 2002338494 A JP2002338494 A JP 2002338494A
Authority
JP
Japan
Prior art keywords
composition
mucin
derivative
talniflumate
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001316115A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002338494A5 (https=
Inventor
Yuhong Zhou
チョウ ユーホン
Roy C Levitt
シー． レビット ロイ
Nicholas C Nicolaides
シー． ニコレイディス ニコラス
Steve Jones
ジョーンズ スティーブ
Mike Mclane
マクレーン マイク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genaera Corp
Original Assignee
Genaera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US09/774,243 external-priority patent/US6737427B2/en
Priority claimed from US09/920,287 external-priority patent/US20020165244A1/en
Priority claimed from US09/951,906 external-priority patent/US20020147216A1/en
Application filed by Genaera Corp filed Critical Genaera Corp
Publication of JP2002338494A publication Critical patent/JP2002338494A/ja
Publication of JP2002338494A5 publication Critical patent/JP2002338494A5/ja
Pending legal-status Critical Current

Links

Landscapes

  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2001316115A 2000-10-23 2001-10-12 ムチン合成インヒビター Pending JP2002338494A (ja)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US24213400P 2000-10-23 2000-10-23
US60/242,134 2000-10-23
US25205200P 2000-11-20 2000-11-20
US60/252,052 2000-11-20
US09/918,711 2000-11-20
US09/774,243 2000-11-20
US09/774,243 US6737427B2 (en) 2000-01-31 2001-01-31 Mucin synthesis inhibitors
US91871101A 2001-08-01 2001-08-01
US09/920,287 US20020165244A1 (en) 2000-01-31 2001-08-02 Mucin synthesis inhibitors
US09/920,287 2001-08-02
US09/951,906 US20020147216A1 (en) 2000-01-31 2001-09-14 Mucin synthesis inhibitors
US09/951,906 2001-09-14

Publications (2)

Publication Number Publication Date
JP2002338494A true JP2002338494A (ja) 2002-11-27
JP2002338494A5 JP2002338494A5 (https=) 2005-06-30

Family

ID=27559313

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001316115A Pending JP2002338494A (ja) 2000-10-23 2001-10-12 ムチン合成インヒビター

Country Status (1)

Country Link
JP (1) JP2002338494A (https=)

Similar Documents

Publication Publication Date Title
US7504409B2 (en) Mucin synthesis inhibitors
US7345051B2 (en) Mucin synthesis inhibitors
AU2001234671A1 (en) Mucin synthesis inhibitors
Crosby et al. Inhaled ENaC antisense oligonucleotide ameliorates cystic fibrosis-like lung disease in mice
US9492413B2 (en) Use of salt of an acetylsalicylic acid for the treatment of viral infections
Zhang et al. Inhibition of Rac1 activity alleviates PM2. 5-induced pulmonary inflammation via the AKT signaling pathway
US11117865B2 (en) Inhibitors of bromodomain-containing protein 4 (BRD4)
WO2019033122A1 (en) TREATMENT OF PULMONARY DISEASES USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS
Wenzel et al. Endocytic trafficking of HIV gp120 is mediated by dynamin and plays a role in gp120 neurotoxicity
US20050249675A1 (en) Mucin synthesis inhibitors
US20020165244A1 (en) Mucin synthesis inhibitors
US20200354336A9 (en) Treatment of Lung Diseases Using Pharmaceutical Agents that Eliminate Senescent Cells
JP2002338493A (ja) ムチン合成インヒビター
JP2002338494A (ja) ムチン合成インヒビター
TW200305447A (en) Methods and compositions for treating respiratory pathologies
US20020147216A1 (en) Mucin synthesis inhibitors
Zhang et al. A large particle size is required by a nano/micron sized-fluticasone propionate inhalable suspension for asthma treatment
WO2021205341A1 (en) 1-methylnicotinamide for the prevention/treatment of inflammatory airway diseases
Dastidar et al. Drug delivery in respiratory diseases: Current opportunities, molecular and cellular mechanism, and future challenges
US10292986B2 (en) Methods for treating epithelian mesenchymal transition related diseases
AU2002320299A1 (en) Mucin synthesis inhibitors
CN120441676A (zh) PANoptosis作为靶点在筛选治疗乳腺炎药物中的应用
US20190381013A1 (en) Brd4 inhibitor treatment of ige-mediated diseases
WO2025090967A9 (en) Pharmacological agonist of klf2 reduces osteoclast differentiation, inflammation, and covid
Patel Characterising and Treating a Refined Model of Allergic Airways Disease that mimics the key features of Human Asthma

Legal Events

Date Code Title Description
A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20041008

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20041008

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20071025

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20080530